MultiCare Pulmonary Specialists is a multi-physician group located in Tacoma, WA. The site employs an experienced research team comprised of board certified Pulmonologists, Study Coordinators, and an Administrative Assistant. The site is conveniently located near three hospitals and all clinical research is done on site. In addition, the site has a comprehensive patient database that is connected to all MultiCare facilities.
Pulmonary studies include the following therapeutic areas:
Principal Investigator:
Sub-Investigators:
Study Number: PT010005-01—A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Juanita Baker, [email protected], 253-403-0366
Study Number: CCD-0599AA3-02—A 6-week, multi-center, randomized, double-blind, placebo-and active-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide via Pressurized Metered Dose Inhaler) in subjects with chronic obstructive pulmonary disease (COPD).
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: GSK 207609 - A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: D3250C00045—A multi-center, randomized, double-blind, parallel group, placebo-controlled, Phase 3b study to evaluate the safety and efficacy of the Benralizumab 30 mg sc in patients with severe asthma uncontrolled on standard of care treatment.
Study Info
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: PT001102 - A randomized, double-blind, parallel group, multicenter, 24-week study comparing the efficacy and safety of three doses of PT001 to placebo and open label Spiriva Respimat.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: D3250R00023 - A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: IA-001 - A randomized, double-blind, placebo-controlled, dose-ranging study evaluating the safety, pharmacokinetics and clinical benefit of FLUIGIV in hospitalized patients with serious Influenza A infection.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Juanita Baker, [email protected], 253-403-0366
Study Number: VIS410-203 - A Phase 2b, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of Intravenous VIS410 in addition to Oseltamivir (Tamiflu®) compared with Oseltamivir alone in hospitalized adults with Influenza A Infection requiring oxygen support.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: INS1007-201 - A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, tolerability and pharmacokinetics of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis bronchiectasis.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Juanita Baker, [email protected], 253-403-0366
Study Number: BIOGEN 203PF203 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: NDS-CP-001 - A multicenter, open-label study to estimate the effect sizes of HRCT endpoints in response to Glucocorticoid induction therapy in subjects with pulmonary sarcoidosis.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Roland, [email protected], 253-403-0389
Study Number: MERCK MK-7264-030 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Juanita Baker, [email protected], 253-403-0366
Study Number: 018CTXX15001—An observational, multi-center study of the prevalence of cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts.
Study Info
Principal Investigator(s): Michael Raff, MD
Study Coordinator: Dalia Sherif, [email protected], 253-403-2698
Study Number: MK-1654-002—A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Principal Investigator(s): Timothy Murphy, MD
Study Coordinator: Karyna Boykin, [email protected], 253-403-9349